The therapeutic ratio is preserved for radiotherapy or cisplatin treatment in BRCA2-mutated prostate cancers
- 1 April 2011
- journal article
- Published by Canadian Urological Association Journal in Canadian Urological Association Journal
- Vol. 5 (2), e31-e35
- https://doi.org/10.5489/cuaj.10080
Abstract
CUAJ is the only indexed, peer-reviewed journal endorsed and supported by the Canadian Urological Association.Keywords
This publication has 33 references indexed in Scilit:
- A Small Interfering RNA Screen of Genes Involved in DNA Repair Identifies Tumor-Specific Radiosensitization by POLQ KnockdownCancer Research, 2010
- Increased Chromosomal Radiosensitivity in Women Carrying BRCA1/BRCA2 Mutations Assessed With the G2 AssayInternational Journal of Radiation Oncology*Biology*Physics, 2010
- A High-Throughput Pharmaceutical Screen Identifies Compounds with Specific Toxicity against BRCA2-Deficient TumorsClinical Cancer Research, 2010
- Late Residual γ-H2AX Foci In Murine Skin are Dose Responsive and Predict RadiosensitivityIn VivoRadiation Research, 2010
- Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy: Observational Study of Veterans With Prostate CancerJNCI Journal of the National Cancer Institute, 2009
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation CarriersThe New England Journal of Medicine, 2009
- BRCA1 modulates malignant cell behavior, the expression of survivin and chemosensitivity in human breast cancer cellsInternational Journal of Cancer, 2009
- BRCA1 and BRCA2 heterozygosity and repair of X-ray-induced DNA damageInternational Journal of Radiation Biology, 2002
- Cells deleted for Brca2 COOH terminus exhibit hypersensitivity to gamma-radiation and premature senescence.1998
- Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2Nature, 1997